TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Bio Vitos Pharma AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Turnover |
114
|
3,035
|
1,249 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-20,697
|
-13,035
|
-14,094 |
| EBITDA |
-3,422
|
-3,550
|
-7,354 |
| Total assets |
16,827
|
34,361
|
25,019 |
| Current assets |
391
|
5,179
|
4,940 |
| Current liabilities |
407
|
1,021
|
1,444 |
| Equity capital |
16,419
|
33,340
|
23,575 |
| - share capital |
5,912
|
4,334
|
2,926 |
| Employees (average) |
1
|
1
|
5 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Solvency |
97.6%
|
97.0%
|
94.2% |
| Turnover per employee |
114
|
3,035
|
250 |
| Profit as a percentage of turnover |
-18155.3%
|
-429.5%
|
-1128.4% |
| Return on assets (ROA) |
-123.0%
|
-37.9%
|
-56.3% |
| Current ratio |
96.1%
|
507.2%
|
342.1% |
| Return on equity (ROE) |
-126.1%
|
-39.1%
|
-59.8% |
| Change turnover | |||
| Change turnover % | 18% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % | -17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.